Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study

被引：0
|
作者：
Fitoussi, O.
Guichard, F.
Hirt, S.
Dohollou, N.
Bureau, C.
Auduhy, F.
Guichard, P.
机构：
[1] Polyclin Bordeaux N Aquitaine, Bordeaux, France
[2] Merck Lipha Sante, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.16027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16027
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Fixed dose schedule of suramin in hormone-refractory metastatic prostate cancer:: A multicenter phase II study.
    Calvo, E
    Cortes, J
    Rodriguez, J
    Sureda, M
    Beltran, C
    Rebollo, J
    Martínez-Monge, R
    de Irala, J
    Fernandez-Hidalgo, O
    Brugarolas, A
    ANNALS OF ONCOLOGY, 2000, 11 : 76 - 77
  • [42] A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma
    Ferrari, AC
    Chachoua, A
    Singh, H
    Rosenthal, M
    Taneja, S
    Bednar, M
    Mandeli, J
    Muggia, F
    CANCER, 2001, 91 (11) : 2039 - 2045
  • [43] A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Lin, Amy M.
    Rini, Brian I.
    Derynck, Mika K.
    Weinberg, Vivian
    Park, Margaret
    Ryan, Charles J.
    Rosenberg, Jonathan E.
    Bubley, Glenn
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2007, 5 (05) : 323 - 328
  • [44] Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma - A phase II study
    Bracarda, S
    Tonato, M
    Rosi, P
    De Angelis, V
    Mearini, E
    Cesaroni, S
    Fornetti, P
    Porena, M
    CANCER, 2000, 88 (06) : 1438 - 1444
  • [45] IDENTIFICATION OF ANTIBODY RESPONSES INDUCED IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) RECEIVING GVAX IMMUNOTHERAPY FOR PROSTATE CANCER
    Clift, S.
    Harding, T.
    Nguyen, M.
    Koprivnikar, K.
    Huan-Tu, G.
    Sacks, N.
    Small, E.
    Jooss, K.
    JOURNAL OF GENE MEDICINE, 2009, 11 (12): : 1139 - 1140
  • [46] Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPCa).
    Sison, B
    Bond, T
    Amato, RJ
    Crawford, D
    Crighton, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 431S - 431S
  • [47] A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer
    Oh, WK
    Hagmann, E
    Manola, J
    George, DJ
    Gilligan, TD
    Jacobson, JO
    Smith, MR
    Kaufman, DS
    Kantoff, PW
    CLINICAL CANCER RESEARCH, 2005, 11 (01) : 284 - 289
  • [48] Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer
    Cabrespine, A
    Guy, L
    Khenifar, E
    Curé, H
    Fleury, J
    Penault-Llorca, F
    Kwiatkowski, F
    Barthomeuf, C
    Chollet, P
    Bay, JO
    UROLOGY, 2006, 67 (02) : 354 - 359
  • [49] A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer
    Huan, SD
    Natale, RB
    Stewart, DJ
    Sartiano, GP
    Stella, PJ
    Roberts, JD
    Symes, AL
    Finizio, M
    CLINICAL CANCER RESEARCH, 2000, 6 (04) : 1333 - 1336
  • [50] Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer
    Coccaro, M
    Tartarone, A
    Romano, G
    Ardito, R
    Di Renzo, N
    TUMORI, 2005, 91 (04) : 314 - 316
12345